Literature DB >> 18689372

Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height.

Julie E Hoover-Fong1, Kerry J Schulze, John McGready, Hillary Barnes, Charles I Scott.   

Abstract

BACKGROUND: Achondroplasia is the most common short stature skeletal dysplasia, with an estimated worldwide prevalence of 250 000. Body mass index (BMI)-for-age references are required for weight management guidance for children with achondroplasia, whose body proportions are unlike those of the average stature population.
OBJECTIVE: This study used weight and height data in a clinical setting to derive smoothed BMI-for-age percentile curves for children with achondroplasia and explored the relation of BMI with its components, weight and height.
DESIGN: This was a longitudinal observational study of anthropometric measures of children with achondroplasia from birth through 16 y of age.
RESULTS: The analysis included 1807 BMI data points from 280 children (155 boys, 125 girls) with achondroplasia. As compared with the BMI of peers of average stature, the BMI in children with achondroplasia is higher at birth, lacks a steep increase in infancy and a later nadir between 1 and 2 y of age, and remains substantially higher through 16 y of age in both sexes. Patterns of change in height and weight in children with achondroplasia are unique in that there is no overlap in the height distribution after 6 mo of age and no spike in height velocity during infancy or puberty-the 2 periods of greatest linear growth in individuals of average stature.
CONCLUSIONS: Sex- and age-specific BMI curves are available for children with achondroplasia (birth to 16 y of age) for health surveillance and future research to determine associations with health outcomes (eg, cardiovascular disease, diabetes, and indication for and outcome of surgery).

Entities:  

Mesh:

Year:  2008        PMID: 18689372     DOI: 10.1093/ajcn/88.2.364

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  16 in total

1.  Respiratory events and obstructive sleep apnea in children with achondroplasia: investigation and treatment outcomes.

Authors:  Shahla Afsharpaiman; David O Sillence; Mehrdad Sheikhvatan; Jenny E Ault; Karen Waters
Journal:  Sleep Breath       Date:  2011-01-13       Impact factor: 2.816

2.  Achondroplasia: Craniofacial manifestations and considerations in dental management.

Authors:  Afnan Al-Saleem; Asma Al-Jobair
Journal:  Saudi Dent J       Date:  2010-07-14

3.  Growth references for height, weight, and head circumference for Argentine children with achondroplasia.

Authors:  Mariana del Pino; Virginia Fano; Horacio Lejarraga
Journal:  Eur J Pediatr       Date:  2010-10-12       Impact factor: 3.183

4.  Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.

Authors:  Celeste Decker; Zi-Fan Yu; Roberto Giugliani; Ida Vanessa D Schwartz; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; J Edmond Wraith; Michael Beck; Laila Arash; Maurizio Scarpa; David Ketteridge; John J Hopwood; Barbara Plecko; Robert Steiner; Chester B Whitley; Paige Kaplan; Stuart J Swiedler; Susan Conrad; Paul Harmatz
Journal:  J Pediatr Rehabil Med       Date:  2010

5.  [Clinical features and FGFR3 mutations of children with achondroplasia].

Authors:  Hui-Qin Zhang; Dong-Ying Tao; Jing-Jing Zhang; Huan-Hong Niu; Jian-Feng Luo; Sheng-Quan Cheng
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

Review 6.  International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia.

Authors:  Ravi Savarirayan; Penny Ireland; Melita Irving; Dominic Thompson; Inês Alves; Wagner A R Baratela; James Betts; Michael B Bober; Silvio Boero; Jenna Briddell; Jeffrey Campbell; Philippe M Campeau; Patricia Carl-Innig; Moira S Cheung; Martyn Cobourne; Valérie Cormier-Daire; Muriel Deladure-Molla; Mariana Del Pino; Heather Elphick; Virginia Fano; Brigitte Fauroux; Jonathan Gibbins; Mari L Groves; Lars Hagenäs; Therese Hannon; Julie Hoover-Fong; Morrys Kaisermann; Antonio Leiva-Gea; Juan Llerena; William Mackenzie; Kenneth Martin; Fabio Mazzoleni; Sharon McDonnell; Maria Costanza Meazzini; Josef Milerad; Klaus Mohnike; Geert R Mortier; Amaka Offiah; Keiichi Ozono; John A Phillips; Steven Powell; Yosha Prasad; Cathleen Raggio; Pablo Rosselli; Judith Rossiter; Angelo Selicorni; Marco Sessa; Mary Theroux; Matthew Thomas; Laura Trespedi; David Tunkel; Colin Wallis; Michael Wright; Natsuo Yasui; Svein Otto Fredwall
Journal:  Nat Rev Endocrinol       Date:  2021-11-26       Impact factor: 47.564

Review 7.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

8.  Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.

Authors:  Celine Saint-Laurent; Stephanie Garcia; Vincent Sarrazy; Karine Dumas; Florence Authier; Sophie Sore; Albert Tran; Philippe Gual; Isabelle Gennero; Jean-Pierre Salles; Elvire Gouze
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

Review 9.  Optimal management of complications associated with achondroplasia.

Authors:  Penny J Ireland; Verity Pacey; Andreas Zankl; Priya Edwards; Leanne M Johnston; Ravi Savarirayan
Journal:  Appl Clin Genet       Date:  2014-06-24

10.  Limb lengthening in achondroplasia.

Authors:  Sanjay K Chilbule; Vivek Dutt; Vrisha Madhuri
Journal:  Indian J Orthop       Date:  2016 Jul-Aug       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.